Canadian Institutes of Health Research, GlaxoSmithKline Inc. and University of Ottawa partner to fund the new J. David Grimes Research Chair

September 14, 2005

This press release is also available in French.

Ottawa, ON (September 14, 2005) - Dr. Leo Renaud, Associate Director and Senior Scientist, Ottawa Health Research Institute and Director of Research, Department of Medicine, University of Ottawa, today has been appointed the first Dr. J. David Grimes Research Chair at the University of Ottawa.

The University of Ottawa, the Ottawa Health Research Institute, GlaxoSmithKline Inc. and the Canadian Institutes of Health Research (CIHR) partnered to fund the $2 million Grimes Chair.

According to Neuroscience Canada, more than 10 million (one in three) Canadians of all ages are affected by neurological and psychiatric disorders and half of all Canadians - about 15 million people - have had a brain disorder impact their family. This daily struggle demands more research into why these disorders occur. Associated health care costs will increase dramatically within the next decade due to the aging population.

"The research chair announced today is an example of how health research is transforming our health care system," said the Honourable Mauril Bélanger, Minister of Internal Trade, Deputy Leader of the Government in the House of Commons and Member of Parliament for Ottawa-Vanier. "This transformation is not only in terms of understanding and treatment of these disorders, but our talented researchers will help to drive the development of new health products and services, attract investment and create jobs for Canada's highly trained workforce."

This important new research position will explore brain cell function to advance the understanding and treatment of neurological and psychiatric disorders such as Parkinson's disease, epilepsy, schizophrenia and depression. Brain disorders are a leading cause of disability and death and represent 14 per cent of the total economic burden of health costs in the country.

"I am delighted to be appointed the first Dr. J. David Grimes Research Chair," said Dr. Leo Renaud. "I am convinced that the best approach for finding the causes and possible cures for many neurological and psychiatric disorders is to advance our understanding of the basic cellular and molecular biology of brain cells."

"Cooperation is a cornerstone of excellence in education, good research and advancing the cause of science," said uOttawa President Gilles Patry. "Our students, our professors and our talented research community will benefit from this exciting partnership."

"GlaxoSmithKline is dedicated to supporting vital research that will ultimately help people who suffer from neurological and psychiatric disorders," said Paul Lucas, President & CEO, GlaxoSmithKline Inc. "Our contribution comes from the GlaxoSmithKline Pathfinders Fund for Leaders in Canadian Health Science Research, an initiative that encourages health science research and fosters medical innovation in Canadian medical schools."

The chair is named for the significant contributions of Dr. J. David Grimes, founder of the Loeb Research Institute (forerunner of the Ottawa Health Research Institute), to the development of medical research at the University of Ottawa.

"It is particularly fitting that Dr. Renaud be chosen for the Grimes Chair as he was recruited from McGill by Dr. Grimes in 1990 to be the first head of the Neurosciences Program in the former Loeb Institute," said Dr. Ronald Worton, CEO and Scientific Director of the Ottawa Health Research Institute. "Dr. Renaud has been one of Canada's most outstanding neuroscientists for over three decades and this is a wonderful recognition of his international stature as a scientist and his many contributions to the Ottawa Health Research Institute and the University of Ottawa."

"Today's announcement demonstrates CIHR's commitment to improving the lives of Canadians," said Dr. Nancy Edwards, CIHR Governing Council Member. "The knowledge generated by Dr. Renaud will increase our scientific understanding of neurological and psychological disorders and help identify the best possible solutions to alleviate this social and economic burden."
-end-
About the Partners

University of Ottawa
The University of Ottawa is North America's largest bilingual university, with over 30,000 students studying and living in both of Canada's official languages. Over 1,000 faculty and researchers are involved in cutting-edge research in all major fields, and the University receives over $150 million each year in research funding. Visit www.uottawa.ca for more information.

Ottawa Health Research Institute
The Ottawa Health Research Institute (OHRI) is a research institute of The Ottawa Hospital and the University of Ottawa. With more than 300 scientists and investigators, 300 students, 500 support staff, and $70 million in external funding, the OHRI is one of the fastest growing and most respected hospital-based research institutes in Canada. For additional information, visit www.ohri.ca.

GlaxoSmithKline Inc.
GlaxoSmithKline Inc. - one of the world's leading research-based pharmaceutical and health-care companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. In Canada, GlaxoSmithKline is a top 20 investor in research and development, and contributed more than $140 million in 2004 alone. For more information visit www.gsk.ca.

Canadian Institutes of Health Research
The Canadian Institutes of Health Research (CIHR) is the Government of Canada's agency for health research. CIHR's mission is to create new scientific knowledge and to catalyze its translation into improved health, more effective health services and products, and a strengthened Canadian health care system. Composed of 13 Institutes, CIHR provides leadership and support to close to 10,000 health researchers and trainees across Canada. For further information, please visit www.cihr-irsc.gc.ca.

For more information, please contact:

University of Ottawa
Bob LeDrew
613-562-5800, ext. 3154
Bob.ledrew@uOttawa.ca

GlaxoSmithKline Inc.
Alison Steeves / Melinda McInnes
905-819-3363

Ottawa Health Research Institute
Jennifer Paterson
613-798-5555, ext. 19691

Canadian Institutes of Health Research
Marie-France Poirier
613-941-4563

Canadian Institutes of Health Research

Related Psychiatric Disorders Articles from Brightsurf:

Sexual minorities, especially women, who misuse substances more likely to have psychiatric disorders
More than half of lesbian, gay and bisexual individuals who misuse alcohol or tobacco also have a co-occurring psychiatric disorder, compared to one-third of heterosexuals, a new University of Michigan study finds.

Internet gaming youth not more prone to psychiatric disorders
Children who show addiction-like gaming signs are not any more susceptible to mental health problems than their non-gaming peers.

People with coronavirus symptoms more likely to have psychiatric disorders and loneliness
People who have or had COVID-19 symptoms are more likely to develop general psychiatric disorders and are lonelier, with women and young people more at risk, says a just-published study co-authored at Cambridge Judge Business School.

Brain structural elements in psychiatric disorders
While researchers have previously identified brain structural signatures associated with individual neurological diseases using techniques such as magnetic resonance imaging (MRI), a team of scientists based in Germany, in a new study, has compared data from multiple studies to find brain structural abnormalities shared between four different neuropsychiatric conditions.

Psychiatric disorders after first birth reduce likelihood of subsequent children
Women who suffer from psychiatric disorders such as depression, anxiety, mania and schizophrenia following the live birth of their first child are less likely to go on to have more children, according to the first study to investigate this in a large nationwide population.

International study completes the largest genetic map of psychiatric disorders so far
An international study published in the journal Cell, has described 109 genetic variants associated with eight psychiatric disorders: autism, ADHD, schizophrenia, bipolar disorder, depression, obsessive-compulsive disorder and Tourette Syndrome, in a total of about 230,000 patients worldwide.

Are there shared genetic factors between weight and major psychiatric disorders?
Data from 1.3 million people were used to investigate genetic overlap between body mass index and major psychiatric disorders such as schizophrenia, bipolar disorder and major depression.

How are psychiatric disorders linked to infections during pregnancy?
Severe infections during pregnancy have been connected to a range of psychiatric disorders by different studies in humans and animals.

Repeated febrile convulsions linked to epilepsy and psychiatric disorders
The risk of febrile convulsions increases with the child's fever, and children who suffer from repeated febrile convulsions during their first year of life have an increased risk of developing epilepsy and psychiatric disorders later in life.

Serum neurofilament is a discriminative biomarker between frontotemporal dementia and psychiatric disorders
Early symptoms of frontotemporal dementia are often confused with symptoms occurring in psychiatric disorders.

Read More: Psychiatric Disorders News and Psychiatric Disorders Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.